Noile-Immune BiotechTSE:4893 +1.65%53 Quick Ratio is 53.51 as of Dec. 2025, which is 1% above its 10-year median of 52.98. GuruFocus rates TSE:4893 with a GF Score™ of 53/100 and a GF Value™ of 円4.36 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,412 Biotechnology companies, Noile-Immune Biotech ranks better than 99.29% on this metric.
Noile-Immune Biotech has a quick ratio of 53.51. It generally indicates good short-term financial strength.
The historical rank and industry rank for Noile-Immune Biotech's Quick Ratio or its related term are showing as below:
TSE:4893'
s Quick Ratio Range Over the Past 10 Years
Min: 13.67 Med: 52.98 Max: 68.65
Current: 62.49
During the past 6 years, Noile-Immune Biotech's highest Quick Ratio was 68.65. The lowest was 13.67. And the median was 52.98.
TSE:4893's Quick Ratio is ranked better than 99.29% of 1412
companies
in the Biotechnology industry
Industry Median: 3.6
vs TSE:4893: 62.49
Noile-Immune Biotech (TSE:4893) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Noile-Immune Biotech Quick Ratio Related Terms
Noile-Immune Biotech Quick Ratio Historical Data
* Premium members only.
The historical data trend for Noile-Immune Biotech's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4893 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Noile-Immune Biotech's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Noile-Immune Biotech Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Noile-Immune Biotech's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Noile-Immune Biotech's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Noile-Immune Biotech's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Noile-Immune Biotech (TSE:4893) has a Quick Ratio of 53.51 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Noile-Immune Biotech and its competitors. This is near median its historical median of 52.98. Over the past decade, Noile-Immune Biotech's Quick Ratio has ranged from 13.67 to 68.65. According to the industry distribution chart, Noile-Immune Biotech ranks #10 out of 1412 companies in the Biotechnology industry, placing it in the top 0.7%.
Is Noile-Immune Biotech's Quick Ratio too high?
Noile-Immune Biotech's current Quick Ratio of 53.51 is near median its 10-year median of 52.98. Over the past 10 years, this metric has ranged from a low of 13.67 to a high of 68.65. The Biotechnology industry median Quick Ratio is 3.60. Noile-Immune Biotech's value of 53.51 is 1386.4% above this industry median. Based on the distribution chart, Noile-Immune Biotech ranks #10 out of 1412 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Noile-Immune Biotech has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noile-Immune Biotech's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Noile-Immune Biotech ranks #10 out of 1412 companies for Quick Ratio. This places Noile-Immune Biotech in the top 1% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Noile-Immune Biotech's value of 53.51 is 1386.4% above this benchmark. Historically, Noile-Immune Biotech's own Quick Ratio has ranged from 13.67 to 68.65 over the past decade. While the company's 10-year median is 52.98 vs. the industry median of 3.60, Noile-Immune Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Noile-Immune Biotech's current Quick Ratio of 53.51 is 1386.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Noile-Immune Biotech and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Noile-Immune Biotech's current Quick Ratio is 53.51, which is near median its own 10-year median of 52.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noile-Immune Biotech stock overvalued right now?
Based on GuruFocus' analysis, Noile-Immune Biotech (TSE:4893) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.36, compared to a current price of 円123.00 — trading 2721.1% above its estimated fair value. The current Quick Ratio is 53.51, which is near median its 10-year median of 52.98 and 1386.4% above the Biotechnology industry median of 3.60. Noile-Immune Biotech's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Noile-Immune Biotech (TSE:4893), the current Quick Ratio is 53.51 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Noile-Immune Biotech (TSE:4893) Overvalued in 2026?
Based on GuruFocus' analysis, Noile-Immune Biotech stock appears to be overvalued.
The current stock price of 円123.00 is trading 2721.1% above its estimated GF Value™ of 円4.36.
GuruFocus considers Noile-Immune Biotech to be Significantly Overvalued.
Key valuation signals for TSE:4893:
Quick Ratio: 53.51 (near median its 10-year median of 52.98)
GF Value™: 円4.36 vs. price of 円123.00 (2721.1% above fair value)
Industry Position: 1386.4% above the Biotechnology median (#10 of 1412)
No single metric tells the full story. See the TSE:4893 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Noile-Immune Biotech Inc is engaged in the development of CAR-T cell therapy for solid cancers using its proprietary technology. The company's development pipeline and collaborative projects with other companies include different product candidates such as NIB102, NIB103, NIB104, ADAP01, AUTL01, etc. It operates in a single segment, the cancer immunotherapy drug discovery business.
53GF Score
Get the complete analysis for TSE:4893
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4893 has been successfully added to your 
